Home › Compound Library › BPC-157 (Body Protection Compound)

BPC-157 (Body Protection Compound)

Peptidesubcutaneous · inferred

Pentadecapeptide derived from human gastric juice. Promotes wound healing, tendon and ligament repair, and gastrointestinal mucosal protection. IV elimination half-life ~15 min in rats; IM bioavailability 14-19% (rats), 45-51% (dogs). Therapeutic effects persist far beyond plasma clearance via sustained tissue-level signaling.

Projected serum levels — 250 mcg (≈ 0.25 mg), twice daily

BPC-157 (Body Protection Compound)
BPC-157 (Body Protection Compound) modeled serum levels, 250 mcg (≈ 0.25 mg) twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
BPC-157 (Body Protection Compound) modeled serum levels with a loading dose of 628 mcg, then 250 mcg (≈ 0.25 mg) twice daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 250 mcg (≈ 0.25 mg) twice daily (subcutaneous).

Loading schedule: 628 mcg on day 1, then 250 mcg (≈ 0.25 mg) twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.10 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
16 min
Common dose
250 mcg (≈ 0.25 mg)
Suggested maximum
1k mcg/day
Reference dose range
125–1k mcg (single dose)
Suggested cadence
twice daily

Documented interactions

  • watch
    GHRP-2 (Pralmorelin) + BPC-157 (Body Protection Compound) Stacked effects

    BPC-157 (Body Protection Compound) and GHRP-2 (Pralmorelin) both push the growth hormone receptor in the same direction.

  • watch
    GHRP-6 + BPC-157 (Body Protection Compound) Stacked effects

    BPC-157 (Body Protection Compound) and GHRP-6 both push the growth hormone receptor in the same direction.

  • watch
    HGH (Human Growth Hormone / Somatropin) + BPC-157 (Body Protection Compound) Stacked effects

    BPC-157 (Body Protection Compound) and HGH (Human Growth Hormone / Somatropin) both push the growth hormone receptor in the same direction.

Serum checks 3 modeled interaction pairings for bpc-157 (body protection compound) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L et al. · Frontiers in Pharmacology, 2022 DOI

    First comprehensive PK study (PMID:36588717) of BPC-157 showing IV elimination half-life of 15.2 min in rats, linear pharmacokinetics across doses, and absolute IM bioavailability of 14-19% (rats) and 45-51% (dogs).…

  2. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract Sikiric P et al. · Current Pharmaceutical Design, 2011 DOI

    Extensive review of BPC-157 mechanisms including cytoprotection, angiogenesis promotion, NO-system modulation, and demonstrated healing effects across multiple GI injury models.

  3. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity Sikiric P et al. · Pharmaceuticals, 2024 DOI

    Updated review of BPC-157 pleiotropic activity including interactions with dopaminergic, serotonergic, GABAergic, and opioid systems, and evidence for neuroprotective effects.

3 published studies referenced in the app, each with a plain-language summary.